Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 13 December, 2005

XTL Biopharm Ltd

Negotiations for Appointment of a CEO


           Negotiations for Appointment of a Chief Executive Officer           

Rehovot, Israel; Tuesday, December 13, 2005 - XTL Biopharmaceuticals Ltd.
('XTLbio') (LSE: XTL; NASDAQ: XTLB; TASE: XTL), a drug discovery and
development company, today announced an update of XTLbio's search for a Chief
Executive Officer. Since March this year, XTLbio has been actively searching
for a US based CEO to lead XTLbio. Following a newspaper article published in
an Israeli evening newspaper on Sunday, XTLbio confirmed that it is in
negotiations with a US based candidate for the position of CEO of XTLbio.
XTLbio indicated that such negotiations are still ongoing and have not been
finalized and therefore XTLbio did not provide any additional details.


About XTL Biopharmaceuticals Ltd.

Established in 1993, XTL Biopharmaceuticals Ltd. (LSE: XTL; NASDAQ: XTLB; TASE:
XTL) is a biopharmaceutical company engaged in the acquisition, development and
commercialization of pharmaceutical products for the treatment of infectious
diseases, particularly the prevention and treatment of hepatitis B and C.

Cautionary Statement

Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the U.S. Private Securities Litigation Reform Act of
1995. Among the factors that could cause our actual results to differ
materially, and therefore affect interest by investors in our ADR's, are the
following: our ability to successfully complete cost-effective clinical trials
for the drug candidates in our pipelines and other risk factors identified from
time to time in our reports filed with the regulatory authorities in Israel,
the United Kingdom and the United States. Any forward-looking statements set
forth in this press release speak only as of the date of this press release. We
do not intend to update any of these forward-looking statements to reflect
events or circumstances that occur after the date hereof. This press release
and prior releases are available at www.xtlbio.com. The information in our
website is not incorporated by reference into this press release and is
included as an inactive textual reference only.


                                                                                                                                                                                                                                                

a d v e r t i s e m e n t